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Oﬁcial de la Federación, 23-04-07). Results are expressed as AE
or its treatment cost in US dollars. RESULTS: Eight oncologists
participated in the Panel. Consensus was achieved for all items
after the questionnaire’s second ﬁlling round. Second line treat-
ment for NSCLC cost estimate was $5377.46 (includes four
chemotherapy cycles with docetaxel, administration costs and
premedication costs). Estimated cost for AEs per event was: RA
$112.13, AN $140.50, NS $194.56, VO $243.08, DR $243.64,
HS $251.56, NP $495.27, TC $948.00, PNA $1167.02, DS
$1807.86, AX $1939.88, ST $2055.82, FN $2527.39, and ILD
$5189.02. CONCLUSION: ILD was the most expensive AE due
to NSCLC treatment, while the most costly were those incurring
in emergency room visits and/or patient hospitalization.
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OBJECTIVE: Non-melanoma skin cancer incidence is increasing
yet no speciﬁc guidelines for treatment selection exist. Reports
vary on surgical treatment efﬁcacy, and treatment choice may be
based in-part on costs, despite little comparative cost informa-
tion. We compared 2007 treatment costs of the three most
common nonmelanoma skin cancer treatments: tumor destruc-
tion by ED&C, excision, and histologically-guided serial excision
(Mohs surgery). METHODS: We studied 936 consecutive non-
melanoma skin cancers diagnosed in 1999–2000 in a university-
afﬁliated dermatology practice. Clinical and utilization data were
obtained from patient surveys and medical records. We deter-
mined cost of treatments, repairs, pathology, and biopsies based
on size, lesion location, number of Mohs stages, medications,
and physician visits, using CPT codes and Medicare fees. We
controlled for procedure risk-selection factors in our sample.
RESULTS: A total of 27.2% of lesions were treated with ED&C,
29.2% with excision, and 43.6% with Mohs surgery. The
weighted average costs per lesion for initial treatment for ED&C,
excision, and Mohs were $221, $529, and $1287, respectively.
When wound repairs, pathology, drug costs and follow-up
physician visits were included, costs rose to $646, $1531, and
$2805. When controlling for risk selection using Mohs sample
for baseline risk, initial costs changed little ($232, $578, $1287).
However, when adding all costs to the controlled sample, the
totals rose to $1750, $2096, and $2805, and differences across
treatments diminished. The uncontrolled costs of Mohs proce-
dure itself (46%) accounts for a greater percentage of total costs
compared with the other two procedures (35%, 34%), and more
than subsequent repair costs (31%, 20% 2%). CONCLUSION:
Mohs surgery was the most costly procedure, however cost dif-
ferences across treatments diminished when controlling for treat-
ment selection factors. This is the ﬁrst cost study which compares
surgical treatment costs using the new (2007) Medicare/CPT
costing rules allowing higher payments for increased complexity
of lesion location.
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OBJECTIVE: To assess the impact of the human immunodeﬁ-
ciency virus (HIV) on the pathogenesis of human papillomavirus
(HPV) infection, precancerous lesions, invasive cervical cancer,
and total treatment costs in South African women. Invasive
cervical cancer is the second most common cancer among South
African women. The high prevalence of HIV in South Africa
(18%) is likely a contributing factor to the high rates of cervical
cancer, as immunocompromised patients are at higher risk of
HPV infection and associated precancerous lesions. METHODS:
We developed a lifetime Markov simulation model of the natural
history of cervical neoplasia and HIV infection. The model was
used to predict the impact of HIV and acquired immunodeﬁ-
ciency syndrome (AIDS)-related mortality on the course of cer-
vical disease in a hypothetical cohort of 100,000 South African
women. Clinical data were based on published South African
literature, high-quality clinical studies, and expert opinion. Risk
of progression of HIV/AIDS was based on CD4 cell counts and
viral load levels. Primary outcome measures included lifetime
risk of cervical intraepithelial neoplasia and cervical cancer, years
of life saved, quality-adjusted life years saved (QALYs), and total
lifetime costs. RESULTS: Lifetime risk of cervical cancer ranged
from 2.3% among HIV-negative women to 3.3% in HIV-positive
women. In a cohort of 100,000 women, the high rate of HIV
infection in South Africa led to an additional 5200 HPV infec-
tions, 490 cervical cancers, and 175 cervical cancer deaths. HIV
infection decreased average life expectancy among South African
women by 3.31 years or 3.28 QALYs and increased costs by
approximately Rand 21,400 per woman. CONCLUSION: HIV
infection contributes to higher rates of invasive cervical cancer
and increases costs. Given the high prevalence of HIV infection in
South Africa, more frequent cervical cancer screening for HIV-
positive women may be warranted.
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OBJECTIVE: The few workloss studies of prostate cancer
patients are short-term and single-treatment focused. We
compare long-term patterns of workloss and costs of 5414 newly
diagnosed patients over 10 years stratiﬁed by treatment type, age
and risk group. METHODS: Workloss patterns for prostate
cancer were identiﬁed using CaPSURE, a national disease registry
that includes clinical data and patient-reported outcome ques-
tionnaires, including demographics, co-morbidity, risk, and work
patterns at 31 academic and community urology practices. Both
change in work status (decreased if changed from full to part-
time or disability, increased if changed back to full time, or no
change) and hours lost were assessed at six-month intervals over
ten years. National hourly wages were used to determine work-
loss costs by age, disease risk, and treatment type. RESULTS:
Patients reported average weekly work reductions of 15.7 hours
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in the ﬁrst 6 month period resulting in $6310 in lost wages. This
loss decreased in the 2nd 6 month period as 6.2% reported
increasing work status, 88% stayed the same, and 5.2% reported
additional decreases, which continued into the ﬁrst half of year 2.
Work loss then increased to 7% until 6 years post treatment
when it slowly decreased. Hours of work loss and gain over 10
years resulted in a weighted cumulative average wage loss of
$146,500. Those at moderate risk lost more wages than high or
low risk patients. Most wages were lost by those receiving andro-
gen deprivation therapy medications alone ($190,000), while
those receiving cryotherapy had the lowest wage loss ($99,500).
Radical prostatectomy treatment alone resulted in $142,100 lost
wages over 10 years. CONCLUSION: The wages lost after treat-
ment for prostate cancer are high. This is the ﬁrst long-term look
at prostate cancer workloss. Although most wage loss occurs in
the ﬁrst six months, substantial loss continues over the next ten
years.
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OBJECTIVE: Metastatic bone disease (MBD) and subsequent
skeletal-related events (SREs) are common complications second-
ary to solid tumors. We conducted a retrospective analysis of
US health insurance claims to examine the cost of SREs among
patients with MBD secondary to breast, lung, or prostate cancer.
METHODS: Data were obtained from i3’s Lab Rx Database
from May 1, 2000 to March 31, 2005. Patients were included if
they had at least two ICD-9 diagnoses of breast, lung, or prostate
cancer; at least two diagnoses of MBD; and at least one SRE on
or after the initial MBD diagnosis. SREs were deﬁned as a patho-
logical fracture, spinal cord compression, surgery to the bone, or
radiation to the bone and were identiﬁed using ICD-9 and CPT-4
codes. Patients had to be continuously insured for at least six
months prior to their ﬁrst SRE (index date) and one month after
their index date. Descriptive statistics were calculated and the
annual cost of SREs was estimated using Kaplan-Meier curves
to adjust for censoring. RESULTS: In the study period, 3584
patients were diagnosed with breast, lung, or prostate cancer and
MBD, and 1840 (51%) experienced at least one incident SRE.
Regardless of tumor type, patients were most frequently found to
have radiation therapy (86%–89%) followed by pathological
fracture (23%–29%), bone surgery (12%–16%), and spinal cord
compression (7%–9%). The adjusted mean costs associated with
SREs in the one year after the index SRE ranged from $12,469 to
$17,408, with the highest costs associated with radiation therapy
($5930 to $7152), pathological fracture ($3179 to $6624), and
bone surgery ($2218 to $2536). CONCLUSION: This analysis
of patients with cancer-related MBD revealed that the incidence
of SREs is high and their annual economic impact is substantial
regardless of tumor type.
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OBJECTIVE: Multiple myeloma (MM) is characterized by the
accumulation of monoclonal plasma cells and osteolytic bone
destruction and is complicated by skeletal-related events (SREs)
which are associated with signiﬁcant morbidity. We conducted a
retrospective analysis of US health insurance claims to examine
the cost of SREs among patients with MM and at least one SRE.
METHODS: Data were obtained from i3’s Lab Rx Database
from May 1, 2000 to May 31, 2005. Patients were included if
they had at least 2 ICD-9 diagnoses of MM (ICD-9 203.0x);
and at least 1 SRE on or after the initial MM diagnosis. SREs
were deﬁned as a pathological fracture, spinal cord compression,
surgery to the bone, or radiation to the bone and were identiﬁed
using ICD-9 and CPT-4 codes. Patients had be continuously
insured for at least six months prior to their ﬁrst SRE (index date)
and one month after their index date. Descriptive statistics were
calculated and annual cost of SREs was estimated using Kaplan-
Meier curves to adjust for censoring. RESULTS: In the study
period, 876 patients were diagnosed with MM, and 429 (49%)
experienced at least 1 incident SRE. The mean time from MM
diagnosis to index SRE was 259 days. Pathological fracture
(60%) and radiation therapy (59%) were the most frequently
experienced SREs followed by surgery to the bone (23%).
Among these patients, 61% had 1 type of SRE, 27% had 2 types
of SREs and 12% had 3 or more. The mean charges associated
with SREs in the 1 year post SRE was $20,285, with the highest
charges associated with pathological fracture ($11,370), fol-
lowed by bone surgery ($4,020), and radiation therapy ($2,966).
CONCLUSION: This analysis of patients with MM revealed
that the incidence of SREs is high and their annual economic
impact is substantial.
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OBJECTIVE: Document total medical resource utilization and
associated costs to the Medicare system for elderly patients with
high risk (stages IIB/C, IIIA/B, IIIC) or metastatic (stage IV)
malignant melanoma. METHODS: Data was taken from the
Surveillance, Epidemiology, and End Results (SEER)-Medicare
linked database combining clinical information on incident
cancer cases in the US between 1991 and 2002 with longitudinal
(1991–2005) Medicare claims. Subjects aged 65 years with 1
stage IIB or higher melanoma diagnosis were selected. Index
dates was deﬁned as the date of the ﬁrst observed stage IIB or
higher diagnosis. Utilization and costs were descriptively ana-
lyzed for each patient from their index date until death, inter-
ruption of beneﬁts coverage (6 months), or end of the database
(December 31, 2005). RESULTS: A total of 6470 subjects met all
inclusion criteria. Stage distribution was: IIB/C (38%); IIIA/B
(46%); IIIC (1%); IV (15%). Median follow-up was 56, 39, 16,
and 6 months for each stage, respectively. On average, patients
with stage IV disease incurred 3.1 hospital days per month,
compared to 0.5, 0.6, and 1.1 days per month for subjects
with stage IIB/C, IIIA/B, and IIIC melanoma, respectively (all
P < 0.001). Mean inpatient costs for stage IV disease were $3337
per patient per month, versus $589, $880, and $1465 for stages
IIB/C, IIIA/B, and IIIC, respectively (all P < 0.001). Total health
care costs, excluding prescription drugs, were $8190 per patient
per month for stage IV disease, compared to $1703, $2536,
$4880 for stages IIB/C, IIIA/B, and IIIC, respectively (all
P < 0.001). CONCLUSION: This study provides stage-speciﬁc
estimates of resource utilization and costs in high risk and meta-
static melanoma using real-world administrative data. Findings
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